Products of lipid peroxidation in bone tissue as markers of osteopenia in patients with chronic lymphocytic leukemia
Abstract
Summary. Chronic lymphocytic leukemia (CLL) is characterized by loss of bone mineral density (BMD), osteopenia (OP) and osteoporosis with a frequency of up to 67%. The pathogenesis of bone lesions in CLL is unclear and may be related to oxidative stress. The purpose of the work is to investigate the relationship between the content of lipid peroxidation products (LPO) in bone tissue and OP indicators in patients with CLL.
The study was conducted on 40 male patients with CLL aged 50-70 years. Osteodensitometry assessed BMD, T-score, Z-score in the lumbar spine (LS), proximal femoral neck (PFC), and proximal femoral bone (PHB). In group 1 (n=30), patients with CLL had no BMD deviations; in group 2 (n=10) there were signs of AP (T-score from – 1.0 SD to – 2.5 SD). The concentration of total vitamin D3, total and ionized calcium, phosphorus, and testosterone was determined in the serum. The content of isopropanol- and heptane-soluble lipid peroxidation products was determined in the bone tissue homogenate. Statistical processing was carried out using IBM SPSS Statistics v. 23". It has been established that in patients with CLL, in 25% of cases, signs of OP are detected in the PHB based on osteodenitometry indicators. The presence of OP in patients with CLL is accompanied by hypophosphatemia, a decrease in serum concentrations of vitamin D3 and testosterone below reference values, and normal concentrations of total and ionized calcium. In patients with CLL and signs of OP, secondary and final products accumulate in the bone tissue in the heptane phase of the lipid extract, and the final products of oxidative destruction of lipids accumulate in the isopropanol phase. Signs of OP in patients with CLL increase as the serum concentration of phosphorus, vitamin D3, testosterone decreases and the content in bone tissue of secondary and end products of oxidative destruction of lipids in the heptane and isopropanol phase of the lipid extract increases.
Downloads
References
2. Chennamadhavuni A, Lyengar V, Mukkamalla SKR, Shimanovsky A. Leukemia. 2023 Jan 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan.
3. Wang H, Guo M, Wei H, Chen Y. Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transduct Target Ther. 2023 Mar 1;8(1):92. doi: 10.1038/s41392-023-01347-1
4. D'Arena G, Seneca E, Migliaccio I, De Feo V, Giudice A, La Rocca F, et al. Oxidative stress in chronic lymphocytic leukemia: still a matter of debate. Leuk Lymphoma. 2019 Apr;60(4):867-875. doi: 10.1080/10428194.2018.1509317
5. Danielle M. Brander, Kevin C. Oeffinger, Melissa A. Greiner, Michaela Ann Dinan. Prevalence, screening, treatment, and complications of osteoporosis and osteopenia in Medicare patients with chronic lymphocytic leukemia (CLL). Journal of Clinical Oncology 38, no. 15_suppl. May 25, 2020. doi: 10.1200/JCO.2020.38.15_suppl.e24050
6. Johnston CB, Dagar M. Osteoporosis in Older Adults. Med Clin North Am. 2020 Sep;104(5):873-884. doi: 10.1016/j.mcna.2020.06.004
7. Volchegorskij IA, Dolgushin II, Kolesnikov OL, Cejlikman VJe. Jeksperimental'noe modelirovanie i laboratornaja ocenka adaptivnyh reakcij organizma. Cheljabinsk: ChelGPU, 2000; 167 s. (In Russian).
8. Walker MD, Shane E. Hypercalcemia: A Review. JAMA. 2022 Oct 25;328(16):1624-1636. doi: 10.1001/jama.2022.18331
9. Adhikari S, Mamlouk O, Rondon-Berrios H, Workeneh BT. Hypophosphatemia in cancer patients. Clin Kidney J. 2021 Apr 15;14(11):2304-2315. doi: 10.1093/ckj/sfab078
10. Graklanov V, Popov V. Vitamin D levels in patients with non-Hodgkin lymphoma/diffuse large B-cell lymphoma, chronic lymphocytic leukemia and multiple myeloma. J Int Med Res. 2020 Jul;48(7):300060520943421. doi: 10.1177/0300060520943421
11. Kubeczko M, Nowara E, Spychałowicz W, Wdowiak K, Bednarek A, Karwasiecka D, et al. Efficacy and safety of vitamin D supplementation in patients with chronic lymphocytic leukemia. Postepy Hig Med Dosw (Online). 2016 May 21;70(0):534-41. doi: 10.5604/17322693.1202482
12. Sadeghi M, Fathi M, Gholizadeh Navashenaq J, Mohammadi H, Yousefi M, Hojjat-Farsangi M, et al. The prognostic and therapeutic potential of HO-1 in leukemia and MDS. Cell Commun Signal. 2023 Mar 13;21(1):57. doi: 10.1186/s12964-023-01074-8
13. Maiti GP, Sinha S, Mahmud H, Boysen J, Mendez MT, Vesely SK, et al. SIRT3 overexpression and epigenetic silencing of catalase regulate ROS accumulation in CLL cells activating AXL signaling axis. Blood Cancer J. 2021 May 17;11(5):93. doi: 10.1038/s41408-021-00484-6
14. Belaya Zh.E., Belova K.Yu., Biryukova E.V., Dedov I.I., Dzeranova L.K., Drapkina O.M., et al. Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis. Osteoporosis and Bone Diseases. 2021;24(2):4-47. In Russian). doi.org/10.14341/osteo12930
15. Marcucci G, Domazetovic V, Nediani C, Ruzzolini J, Favre C, Brandi ML. Oxidative Stress and Natural Antioxidants in Osteoporosis: Novel Preventive and Therapeutic Approaches. Antioxidants (Basel). 2023 Feb 3;12(2):373. doi: 10.3390/antiox12020373
16. Gao Y, Patil S, Jia J. The Development of Molecular Biology of Osteoporosis. Int J Mol Sci. 2021 Jul 30;22(15):8182. doi: 10.3390/ijms22158182
17. Vervloet MG. Shedding Light on the Complex Regulation of FGF23. Metabolites. 2022 Apr 28;12(5):401. doi: 10.3390/metabo12050401
